The FDA Lost 3,000 People. Now It Wants to Hire Them All Back.

People are leaving faster than replacements can be processed.

And here's the real kicker: positions funded by PDUFA (the user fees that drug companies pay to fund their own reviews) show zero hires in fiscal year 2026. Not a slow start. Literally zero. That's the program that bankrolls the bulk of new drug reviews. If those positions stay empty, the backlog isn't a risk; it's a certainty.

The Good News (Sort Of)

Despite all this, the FDA managed to approve 46 novel drugs and biologics in 2025 without blowing most of its deadlines. Only two applications exceeded a 12-month review, and those delays were caused by extra data submissions, not staffing shortages. On paper, the system held.

But the cracks are showing. An RBC Capital Markets analysis found that on-time completion rates dropped to 78% in the second half of 2025, down from the historical range of 85 to 90 percent. Biologics approvals fell to just 9 in 2025, compared to 22 and 24 in the two prior years. Internal sources describe reviewers carrying nearly double their usual workload.

The 2025 data looks like a student pulling an all-nighter to pass the final exam. They survived, but nobody should confuse that with sustainable performance.

A New Playbook for Clinical Trials

Alongside the hiring blitz, the FDA is updating how it evaluates whether a drug actually works. The biggest shift: sponsors can now generally rely on one well-designed pivotal trial plus supporting evidence, rather than the traditional two-trial standard.

That single trial needs to be "highly persuasive," meaning randomized, blinded, representative of real patients across multiple sites, and powered to show a clinically meaningful effect (not just a statistically significant blip). The FDA is also expressing a clear preference for clinical endpoints over surrogate markers. Translation: they want to see that a drug makes patients feel better or live longer, not just that it moves a lab number.

To back up that one pivotal trial, companies can submit a range of confirmatory evidence: mechanistic data, real-world evidence, natural history studies, or results from related diseases. The agency also released updated guidance on master protocols (basket, umbrella, and platform trials), which let multiple questions get answered within a single trial framework. Think of it as going from one-question-per-test to a comprehensive exam.

For early-stage development, FDA clarified that Phase 1 applications don't need full analytical validation data or complete stability studies upfront. New guidance on quantitative modeling for first-in-human dosing could make early trials safer and more efficient, especially for high-risk therapies like cell and gene products.

The Trust Problem Nobody Wants to Talk About

Biotech executives greeted the announcements with the enthusiasm of someone who's been promised their delayed flight is "now boarding." They want to believe it, but they've been burned before.

The deeper concern isn't headcount. It's independence. Reports from BIO 2026 indicate that executives want assurance that FDA decision-making won't hinge on any single political appointee. One FDA leader acknowledged the point directly, stating that the agency cannot rely on "an individual" and that sustainable regulation has to be bigger than any one person.

Meanwhile, some biotech companies have already started moving early-stage trials outside the United States. Reuters reported that staffing chaos and unpredictable review timelines pushed at least some firms to explore regulatory paths in other countries first. That's the kind of vote-with-your-feet response that should alarm everyone.

What This Means for Your Portfolio (and Your Prescriptions)

The modernized trial standards are genuinely positive. One pivotal trial instead of two can shave years and hundreds of millions of dollars off development timelines. The emphasis on clinical endpoints and flexible confirmatory evidence reflects how modern drug development actually works.

But standards don't review applications; people do. Until the FDA closes the gap between its hiring goals and the revolving door of departures, every company with a pending NDA or BLA should plan for more variability. Biologics look especially exposed, given the steep drop in BLA approvals and persistent staffing losses at CBER.

The agency's proposed budget for fiscal year 2026 is $6.8 billion, down from $7.2 billion the year before. Hiring 2,200 people with a shrinking budget is the regulatory equivalent of trying to fill a swimming pool with a garden hose while someone drills holes in the bottom.

The FDA has the right plan. Whether it has the resources, the runway, and the political insulation to execute it is a very different question.

J&J Just Built a Robot That Hides Under the Operating Table

J&J's OTTAVA just became the first table-integrated surgical robot to earn FDA authorization, creating an entirely new device category. After a decade of delays, billion-dollar lawsuits, and a $900 million write-down, the fight for Intuitive Surgical's robotic surgery throne just got real.